Insys Therapeutics (INSY) Tops Q4 EPS by 9c

Insys Therapeutics (NASDAQ: INSY) reported Q4 EPS of $0.53, $0.09 better than the analyst estimate of $0.44. Revenue for the quarter came in at $66.5 million versus the consensus estimate of $63.5 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• TD Cowen Reiterates Buy Rating on NVIDIA (NVDA), 'unlikely to move significantly on earnings'